AVROBIO Inc (AVRO)

NASDAQ
1.039
+0.029(+2.87%)
  • Volume:
    19,786
  • Day's Range:
    1.020 - 1.040
  • 52 wk Range:
    0.740 - 6.880

AVRO Overview

Prev. Close
1.01
Day's Range
1.02-1.04
Revenue
-
Open
1.02
52 wk Range
0.74-6.88
EPS
-2.72
Volume
19,786
Market Cap
44.44M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
406,595
P/E Ratio
-0.371
Beta
1.73
1-Year Change
-83.68%
Shares Outstanding
42,776,617
Next Earnings Date
Nov 10, 2022
What is your sentiment on AVROBIO?
or
Vote to see community's results!

AVROBIO Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

AVROBIO Inc Analysis

AVROBIO Inc Company Profile

AVROBIO Inc Company Profile

Employees
122

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company’s product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell